Why does Russia have such high cardiovascular mortality rates? Comparisons of blood-based biomarkers with Norway implicate non-ischaemic cardiac damage

Olena lakunchykova,1 Maria Averina,1,2 Tom Wilsgaard,1 Hugh Watkins,3,4 Sofia Malyutina,5,6 Yulia Ragino,6 Ruth H Keogh,7 Alexander V Kudryavtsev,1,8 Vadim Govorun,9 Sarah Cook,1 Henrik Schirmer,1,10,11 Anne Elise Eggen,1 Lila Arnesdatter Hopstock,1 David A Leon1,12

ABSTRACT

Background Russia has one of the highest rates of mortality from cardiovascular disease (CVD). At age 35–69 years, they are eight times higher than in neighbouring Norway. Comparing profiles of blood-based CVD biomarkers between these two populations can help identify reasons for this substantial difference in risk.

Methods We compared age-standardised mean levels of CVD biomarkers for men and women aged 40–69 years measured in two cross-sectional population-based studies: Know Your Heart (KYH) (Russia, 2015–2018; n = 4046) and the seventh wave of the Tromsø Study (Tromsø 7) (Norway, 2015–2018; n = 17 646).

A laboratory calibration study was performed to account for inter-laboratory differences.

Results Levels of total, low-density lipoprotein-, high-density lipoprotein-cholesterol and triglycerides were comparable in KYH and Tromsø 7 studies. N-terminal pro-b-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT) and high-sensitivity C-reactive protein (hsCRP) were higher in KYH compared with Tromsø 7 (NT-proBNP was higher by 54.1% (95% CI 41.5% to 67.8%) in men and by 30.8% (95% CI 22.9% to 39.2%) in women; hs-cTnT by 42.4% (95% CI 36.1% to 49.0%) in men and by 68.1% (95% CI 62.4% to 73.9%) in women; hsCRP by 33.3% (95% CI 26.1% to 40.8%) in men and by 35.6% (95% CI 29.0% to 42.6%) in women). Exclusion of participants with pre-existing coronary heart disease (279 men and 282 women) had no substantive effect.

Conclusions Differences in cholesterol fractions cannot explain the difference in CVD mortality rate between Russia and Norway. A non-ischemic pathway to the cardiac damage reflected by raised NT-proBNP and hs-cTnT is likely to contribute to high CVD mortality in Russia.

INTRODUCTION

Russia has one of the highest rates of mortality from cardiovascular disease (CVD) in the world,1 although it has been falling since 2005.2 The causes of this high CVD mortality are not fully understood. Comparison of blood-based biomarkers and other risk factors in Russia relative to other countries with lower CVD risk should throw light on the likely drivers of these differences in mortality. A small number of such studies have been conducted with blood-based biomarkers restricted to lipid profiles (total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides).3–6 These have generally found no major differences between Russia and other countries.

Biomarkers such as high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) provide information on actual cardiovascular morbidity and are not simply risk predictors. They have been increasingly used in population-based research where they have been shown to be independent predictors of CVD events.7–9 Outside of acute ischaemic cardiac events, hs-cTnT elevation is associated with future risk of heart failure, which is supported by structural and functional studies of the heart.10 NT-proBNP is used in diagnostics of heart failure and is predictive of heart failure in population-based cohorts,11 along with atrial fibrillation and stroke.12 While some controversy exists about the role of high-sensitivity C-reactive protein (hsCRP) in CVDs,13 it is associated with coronary heart disease, stroke and vascular death independently of the traditional risk factors.14 In fact, studies of large population-based cohorts identified hsCRP, hs-cTnT and NT-proBNP as the blood biomarkers that are the most predictive of cardiovascular events.15

In this paper, data from the Know Your Heart (KYH) study (Russia) and the Tromsø study (Norway) are compared to establish the differences in major cardiovascular biomarkers measured in blood among men and women aged 40–69 years. Norway has a CVD mortality rate approximately eight times lower than that in Russia in this middle-aged group16; thus, it provides a good contrast for comparing CVD biomarker levels.

METHODS

Study populations

Know Your Heart (Russia). A random population-based sample of participants aged 35–69 years (n = 5107) stratified by age, sex and district were recruited in the cities of Arkhangelsk and Novosibirsk (Russia).16 Trained interviewers recruited and interviewed participants at home to
ascertain information about their health, socio-demographic characteristics and lifestyle (51% of approached agreed to participate). Participants were then invited to take part in a health check at an outpatient clinic and 4543 (89%) attended. Our analysis is based on 4046 participants aged 40–69 years who attended the health check and provided a blood sample. The health check included blood pressure measurements, recording of weight and height, a 12-lead ECG and biological sample collection. The additional questionnaire collected data on health problems, lifestyle and medication use. Within 2 hours after venipuncture (non-fasting samples), blood was centrifuged, serum was frozen (−80°C) and analysed in a single batch at the end of the fieldwork in Moscow.16

The Tromsø Study (Norway). In Tromsø 7, all inhabitants of the municipality of Tromsø aged 40 years and above were invited and 21 083 participated (63%). The subset of 17 646 participants aged 40–69 years was included in our analysis. All participants completed questionnaires and examinations including biological sampling. The questionnaire covered lifestyle, medication use and medical history. A random subsample (5963 participants) attended a second visit. Blood samples (non-fasting) at both visits were processed immediately after collection and the laboratory assays of the biomarkers were performed the same day at the Department of Laboratory Medicine, University Hospital of Northern Norway (ISO certification NS-EN ISO 15 189:2012).

Study measurements
All participants in KYH and Tromsø 7 with blood sample collected had measured lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides), a marker of systemic inflammation (hsCRP) and glycosylated haemoglobin (HbA1c)—Supplementary Table S1. A marker of cardiac damage (hs-cTnT) and a marker of cardiac wall stretch (NT-proBNP) were measured in all KYH participants and in 1403 Tromsø 7 participants who were either selected randomly (81%) to attend the second visit or were invited because of their previous participation in the sixth wave of the Tromsø study. The characteristics of those in Tromsø study with measured cardiac biomarkers are very similar to that of the total study sample (Supplementary Table S2).

Body mass index (BMI) was calculated as weight (kilograms) divided by height (metres) squared. Mean systolic and diastolic blood pressure was calculated as the mean of second and third measurements. Waist circumference (WC) was measured at the narrowest part of the trunk in KYH, while in Tromsø 7, WC was measured at the umbilicus level. To ensure WC was comparable between the two studies, WC in Tromsø 7 was converted to the narrowest waist using a conversion equation.17 Waist-to-hip ratio (WHR) was calculated by dividing WC by hip circumference. Smoking status was categorised as current smokers, ex-smokers and never-smokers. For current smokers, the number of cigarettes smoked was specified as 1–10/day, 11–20/day and >20/day. Education level was classified into three categories: primary/secondary, upper secondary and tertiary. Diabetes was defined as HbA1c concentration above 6.5%, or self-report of diabetes, or use of medication with ATC-code A10 (antidiabetics) according to the Anatomical Therapeutic Chemical (ATC) classification.18 Lipid-lowering drugs use was determined according to recorded medications coded to the ATC classification as C10 (lipid-modifying agents) or self-reported use.

The pre-existing coronary heart disease was determined as evidence of previous myocardial infarction (MI) on ECG, self-report of MI or grade 2 angina pectoris. ECGs from both studies were coded according to the Minnesota code (MC 1.1–1.3)19 using the same semi-automated system. Grade 2 angina was determined using the Rose Angina Questionnaire (short version).20

Calibration of laboratory data
Differences in the laboratory procedures in KYH and Tromsø 7 bring the potential for systematic differences in biomarker measurements between the two sites due to measurement error. This was addressed by a recalibration study with split sample testing (Supplementary Methods M1, Supplementary Tables S3–S5, Supplementary Figures S1–S10). For that purpose, 100 serum samples and 50 whole blood samples from KYH participants were re-assayed in both the laboratories in Moscow and Tromsø. The paired measurements were analysed using Deming regression to derive the calibration equations.

Statistical analysis
Mean biomarker levels among men and women were compared having age-standardised to the 2013 Standard European Population. Biomarkers with skewed distributions (triglycerides, hsCRP, hs-cTnT, NT-proBNP) were ln-transformed before analysis and geometrical means were presented. Multivariable linear regression was used to assess if the differences in mean biomarker levels in the two studies could be explained by differences in age (Model1), smoking prevalence, BMI, WHR, blood pressure, diabetes, education level (in addition to age) (Model 2) and use of lipid-lowering drugs (in addition to variables in Model 2) (Model 3). For triglycerides, models were also adjusted for the fasting status. The regression models for hs-cTnT and NT-proBNP were repeated for study participants without previous MI or grade 2 angina. For the regression modelling, data from participants with complete information on all the covariates were used. For skewed biomarkers, the regression coefficients were back-transformed to be interpreted as a per cent difference between studies. Based on finding evidence of an interaction between age and study, the differences in biomarkers between studies were presented separately for 40–54 and 55–69 year olds.

All analyses were done using recalibrated biomarkers (Supplementary Table S5). To account for uncertainty in the estimation of the calibration coefficients in the subsequent comparison analysis, we used a ‘double-bootstrap’ approach, verified using a simulation study (Supplementary Methods M2, Supplementary Tables S6–S7), to obtain 95% CIs for the regression coefficients. Statistical analysis was performed using R version 3.6.0 and SAS software 9.4 (SAS Institute Inc., Cary, NC, USA).

RESULTS
Descriptive characteristics presented in table 1 show that men in KYH were on average older, had higher blood pressure and lower BMI, and a higher proportion were current smokers, and had diabetes, compared with men in Tromsø 7. Women in KYH were on average older, had higher blood pressure and BMI, a higher proportion had diabetes, and a lower proportion were current or previous smokers, compared with women in Tromsø 7 (table 1). The similar proportion of participants reported using lipid-lowering drugs that could be identified by ATC code in KYH and Tromsø 7; however, self-reported use of lipid-lowering drugs was higher in KYH (table 1).

The age-standardised means of CVD biomarkers are compared in table 2. The geometric means for hs-cTnT, NT-proBNP and hsCRP were significantly higher in KYH compared with Tromsø 7 among both men and women. It is notable that KYH had
a higher proportion of participants with detectable hs-cTnT: 98.6% compared with 64.4% in Tromsø 7.

Table 3 shows the conditional differences in mean biomarker levels between the three studies from regression models. The age-adjusted model shows that men and women in KYH had slightly lower LDL- and HDL-cholesterol than in Tromsø 7, while triglyceride levels in women were higher in KYH. Adjustment for pre-existing coronary heart disease did not change the estimate of the mean difference.

Table 1 Characteristics of the study sample (participants aged 40–69 years with blood sample collected): KYH (N=4046) and Tromsø 7 (N=17 555)

| Age group | Men | Women |
|-----------|-----|-------|
| KYH       | 2342 | 1700  |
| Tromsø 7  | 2346 | 1700  |
| Difference | 2342 | 1700  |

Table 2 Age-standardised mean of CVD biomarkers in KYH and Tromsø 7

| Biomarker | KYH | Tromsø 7 | P value for difference |
|-----------|-----|----------|------------------------|
| Total cholesterol (mmol/L) | 3802 | 1700 | <0.001 |
| HDL-cholesterol (mmol/L) | 8302 | 1700 | 0.002 |
| LDL-cholesterol (mmol/L) | 8302 | 1700 | <0.001 |
| Triglycerides (mmol/L) | 425 | 8302 | <0.001 |
| hs-cTnT (mg/L) | 54.7 | 8302 | <0.001 |
| NT-proBNP (pg/mL) | 54.7 | 8302 | <0.001 |
| hs-cTnT (mg/L) | 54.7 | 8302 | <0.001 |
| NT-proBNP (pg/mL) | 54.7 | 8302 | <0.001 |

The differences in hs-cTnT and NT-proBNP remained when the analysis was restricted to participants without previous MI, or grade 2 angina (table 4).

The differences in biomarker levels between the two studies differed by age group (table 5). For most biomarkers, study differences were larger in women aged 55–69 years than 40–54 years. Among men, differences in hsCRP were more pronounced in the older age group (55–69 years), while differences in total and LDL-cholesterol were larger in younger men (40–54 years).

Sensitivity analysis

As hs-cTnT assays are known to show appreciable imprecision at the low values seen in the general population, we conducted a sensitivity analysis using logistic regression with hs-cTnT categorised into values below and above the top quintile in this study distribution (men—11 ng/L, women—8.07 ng/L). The results were consistent with hs-cTnT analysed as a continuous outcome (Supplementary Tables S8–S9). Adjustment for lipid-lowering drugs based only on ATC codes in the regression model produced similar results to the main analysis which defined lipid-lowering drugs based on ATC code and self-reported use.

DISCUSSION

This comparison study shows that, after adjustment for sex and age, the lipid profile was comparable in KYH (Russia) and in Tromsø 7.
and use of lipid-lowering drugs. Not explained by differences in prevalence of classic risk factors related to several pathological processes in the cardiovascular system: heart failure,25 atrial fibrillation26 and stroke.12 We suggest that elevated NT-proBNP in KYH compared with Tromsø 7 may be explained by higher heart damage due to non-ischaemic pathways to heart disease. Although heart damage and the development of chronic heart failure can be facilitated by MI or stable coronary heart disease, our conclusions were robust after exclusion of participants with a history of coronary heart disease.

Table 3 Differences in mean biomarker levels in KYH vs Tromsø 7 adjusted for CVD risk factors

|       | N               | Model 1 (adjusted for age) | Model 2 (adjusted for age, smoking, BMI, WHR, SBP, DBP, diabetes, education) | Model 3 (adjusted for age, smoking, BMI, WHR, SBP, DBP, diabetes, education, lipid-lowering drugs) |
|-------|-----------------|----------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Men   | Total cholesterol | −0.22 (−0.29, −0.1)       | −0.31 (−0.39, −0.19)                                                      | −0.30 (−0.38, −0.17)                                                                          |
|       | HDL             | −0.05 (−0.07, −0.02)       | −0.05 (−0.07, −0.02)                                                      | −0.05 (−0.07, −0.02)                                                                          |
|       | LDL             | −0.26 (−0.34, −0.22)       | −0.32 (−0.41, −0.28)                                                      | −0.31 (−0.39, −0.27)                                                                          |
|       | Triglycerides† | 0.03 (0.00, 0.07)          | 0.02 (−0.01, 0.06)                                                        | 0.02 (−0.01, 0.06)                                                                             |
|       | hsCRP‡         | 0.29 (0.23, 0.35)          | 0.16 (0.10, 0.22)                                                         | 0.17 (0.11, 0.22)                                                                              |
|       | NT-proBNP†      | 0.44 (0.36, 0.53)          | 0.37 (0.27, 0.47)                                                         | 0.37 (0.27, 0.46)                                                                              |
|       | hs-cTnT†       | 0.36 (0.31, 0.40)          | 0.37 (0.32, 0.42)                                                         | 0.37 (0.32, 0.42)                                                                              |

Women

|       | Total cholesterol | −0.07 (−0.15, 0.04)       | −0.13 (−0.21, −0.01)                                                      | −0.09 (−0.17, 0.03)                                                                          |
|       | HDL             | −0.13 (−0.16, −0.11)       | −0.02 (−0.04, 0.01)                                                      | −0.02 (−0.04, 0.01)                                                                          |
|       | LDL             | −0.03 (−0.10, 0.01)        | −0.13 (−0.21, −0.09)                                                      | −0.09 (−0.17, −0.05)                                                                          |
|       | Triglycerides† | 0.10 (0.07, 0.12)          | 0.03 (0.00, 0.06)                                                        | 0.03 (0.00, 0.06)                                                                             |
|       | hsCRP‡         | 0.31 (0.26, 0.35)          | 0.04 (−0.01, 0.10)                                                        | 0.05 (0.11)                                                                                   |
|       | NT-proBNP†      | 0.27 (0.21, 0.33)          | 0.33 (0.25, 0.39)                                                         | 0.32 (0.24, 0.38)                                                                              |
|       | hs-cTnT†       | 0.52 (0.48, 0.55)          | 0.49 (0.45, 0.53)                                                         | 0.49 (0.45, 0.53)                                                                              |

Table 4 The difference in mean levels of NT-proBNP and hs-cTnT in KYH compared with Tromsø 7, adjusted for age.

|                  | Without coronary heart disease | With coronary heart disease |
|------------------|--------------------------------|-----------------------------|
|                  | N | Mean difference (95% CI) | N | Mean difference (95% CI) |
| **Men**          |   |                          |   |                          |
| NT-proBNP†       | 1913 | 0.42 (0.33, 0.51) | 279 | 0.34 (−0.02, 0.68) |
| hs-cTnT†         | 1918 | 0.35 (0.30, 0.40) | 279 | 0.35 (0.17, 0.52) |
| **Women**        |   |                          |   |                          |
| NT-proBNP†       | 2594 | 0.24 (0.18, 0.30) | 282 | 0.49 (0.13, 0.81) |
| hs-cTnT†         | 2598 | 0.52 (0.49, 0.55) | 282 | 0.38 (0.12, 0.58) |

Analysis is stratified by pre-existing coronary heart disease (ECG or self-reported MI, grade 2 angina). Analysis is based on ln-transformed values.

Elevated NT-proBNP is a biomarker of cardiac dysfunction related to several pathological processes in the cardiovascular system: heart failure,23 atrial fibrillation26 and stroke.12 We suggest that elevated NT-proBNP in KYH compared with Tromsø 7 may be explained by higher heart damage due to non-ischaemic pathways to heart disease. Although heart damage and the development of chronic heart failure can be facilitated by MI or stable coronary heart disease, our conclusions were robust after exclusion of participants with a history of coronary heart disease.

High-sensitivity cardiac troponin T

Similar to NT-proBNP, we found higher mean levels of hs-cTnT in KYH compared with Tromsø 7 among both men and women. This was not explained by a different prevalence of classic CVD risk factors (smoking, BMI, WHR, blood pressure, diabetes), but among women, the difference was more

Table 4 The difference in mean levels of NT-proBNP and hs-cTnT in KYH compared with Tromsø 7, adjusted for age.
pronounced in the older age group (55–69 years old). Our study is the first to measure hs-cTnT in a general population in Russia. Several studies in the US and Western Europe used hs-cTnT measurements in population samples free of known CVD to predict future CVD.\(^5\) \(^6\) High hs-cTnT was recognised as an indicator of heart failure rather than ischaemic damage.\(^8\) \(^9\) Biochemical evidence of myocyte injury was associated with subsequent imaging evidence of replacement fibrosis both in the sample of asymptomatic individuals\(^6\) and in symptomatic non-ischaemic heart disease populations.\(^7\) \(^8\) Even in patients with chronic coronary artery disease, hs-cTnT was associated with death and heart failure but not MI.\(^1\) It is notable that exclusion of participants with pre-existing coronary heart disease in our study did not change the estimates of the differences in hs-cTnT substantially, neither did adjustment for hypertension and smoking.

### High-sensitivity C-reactive protein

This marker of systemic inflammation was higher in KYH than in Tromsø 7. The differences are of similar magnitude among men and women, are more pronounced in older age among men and are appreciably attenuated by adjustment for classical CVD risk factors (smoking, BMI, WHR, blood pressure, diabetes). Several previous studies have investigated predictors of increased hsCRP levels in Russian populations but did not report mean levels or systematically compare them with western studies.\(^6\) \(^8\) Raised levels of hsCRP have been found to be predictive of future CVD events\(^8\) \(^9\) and were associated with coronary plaque burden\(^4\) and atherosclerosis\(^3\); however, the relationship is not considered to be causal.\(^1\) \(^3\) Low-grade elevation of hsCRP is non-specific and may reflect exposure to pro-inflammatory influences including smoking, particulate air pollutants, aspects of diet, medications, oral cavity health, obesity and metabolic syndrome.\(^3\) \(^4\) \(^13\) While elevated hsCRP levels in KYH indicate higher general inflammatory status in the participants, this may reflect both atherosclerosis and higher prevalence of CVD risk factors, like obesity and smoking. Although this study does not permit inferences about the prevalence of atherosclerosis, elevated hsCRP may indicate greater risk of future CVD outcomes in the Russian sample.

### Strengths and limitations

We analysed biomarker levels in recently obtained population-based samples of men and women within the same age range in the two studies. Similar methodology was used for data and sample collection. A key strength is that a calibration study was done to ensure the comparability of the laboratory essays for biomarkers. Furthermore, an innovatory approach to calculate CIs of the regression coefficients obtained using calibrated measures was developed to ensure 95% coverage. Because the study was conducted in three cities, and response rates in KYH were not optimal, we should be cautious to generalise the findings to the whole of Norway and Russia. The age distribution of the populations of Novosibirsk and Arkhangelsk was similar to the national average in both cities.\(^16\) Tromsø and Novosibirsk have higher proportion of population with higher education compared with respective national averages.\(^16\) \(^19\) However, it should be noted that the selected locations have CVD mortality rates that are similar to the national averages.\(^16\) Considering the ongoing changes in cardiovascular mortality in Russia, there are many other factors that may explain recent reduction, including improvements in treatment for acute CVD events.\(^7\) However, in this paper, we were focusing on circulating biomarkers in the general population rather than particular high-risk groups.

### CONCLUSIONS

By comparing the blood biomarker profiles in comparable population-based studies conducted in Russia and Norway, the latter a country with much lower CVD mortality rates, we attempted to identify the distinguishing features of CVD epidemic in contemporary Russia that make it unique to the rest of the world. We have found the evidence that non-ischaemic pathways beyond lipid-related mechanisms may take a significant share of CVD morbidity in Russia. The higher levels of NT-proBNP and hs-cTnT in Russia may indicate that this population is at higher risk of dilated cardiomyopathy, heart failure, atrial fibrillation and cardioembolic stroke. Very minor differences in lipid levels are not enough to explain the much high mortality due to coronary heart events in Russia compared with Norway. However, higher pro-inflammatory status reflected by hsCRP and contribution of higher levels of hypertension, BMI and WHR (among women); smoking (among men); and diabetes are very likely to contribute to explaining the high coronary heart disease mortality in Russia. To further explore heart damage, more in-depth characterisation of heart structure and function with echocardiography and carotid ultrasound is required. Exploration of alcohol use as...
a potential explanation of biomarker differences should be a potential future research direction.37

The results of this study are important from a prevention perspective. As we suggest a substantive proportion of CVD in Russia occurring due to non-ischaemic pathways, additional efforts are needed to detect and treat people with early structural and functional changes in the heart.

What is already known on this subject

► Russia has one of the highest rates of mortality from cardiovascular disease (CVD) in the world with the reasons for that not fully understood. A small number of studies measured blood-based biomarkers of CVD in Russia but included only lipid profiles. Comparison of lipid profiles to other countries did not find major differences.

What this study adds

► Levels of total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were similar in two population-based studies conducted in Russia and Norway: Know Your Heart and Tromsø 7. This finding is paradoxical given high cardiovascular mortality rates in Russia. However, markers of cardiac damage and general inflammation were considerably higher in Russian compared with Norwegian study. Non-ischaemic pathways to cardiac damage reflected by raised NT-proBNP and hs-cTnT are likely to contribute to high CVD mortality in Russia.

Author affiliations
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
2Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway
3Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
4Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
5Novosibirsk State Medical University, Russian Ministry of Health, Novosibirsk, Russian Federation
6Research Institute of Internal and Preventive Medicine, Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation
7Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
8Department of Innovative Programs, Northern State Medical University, Arkhangelsk, Russian Federation
9Federal Research and Clinical Center of Physico-Chemical Medicine of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation
10Department of Cardiology, Akerhus University Hospital, Lorenskog, Norway
11Institute of Clinical Medicine, University of Oslo, Oslo, Norway
12Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

Correction notice This article has been corrected since it first published online. The first author’s last name has been corrected to ‘lakunchykova’.

Acknowledgements We would like to acknowledge the participants of the KYH study and the Tromsø study for their contribution.

Contributors Study design: OL, MA, HS, LH, AEE, DAL. Data analysis: OL, TW, RK, DAL. Data interpretation: OL, MA, HW, SM, YR, AK, VG, SC, HS, AEE, LH, DAL. Drafting manuscript: OL and DAL. Revising manuscript content: OL, MA, HW, SM, RK, YR, AK, VG, SC, HS, AEE, LH, DAL. Approving final version of manuscript: All authors.

Funding The KYH study is a component of the International Project on Cardiovascular Disease in Russia (IPCDR). IPCDR was funded by the Wellcome Trust Strategic Award [100217] supported by funds from UiT The Arctic University of Norway; Norwegian Institute of Public Health; the Norwegian Ministry of Health and Social Affairs. The seventh wave of the Tromsø study was funded by UiT The Arctic University of Norway, Northern Norway Regional Health Authority, Norwegian Ministry of Health and Social Services, and Troms County. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethical approval Ethical approval for the study was received from the ethics committees of the London School of Hygiene & Tropical Medicine (approval number 8808, 24/02/2015), Novosibirsk State Medical University (approval number 75, 21/05/2013), the Institute of Preventative Medicine (no approval number; 26/12/2014), Novosibirsk and the Northern State Medical University, Arkhangelsk (approval number 01:101-15, 27/01/2015). The Regional Committee for Research Ethics approved Tromsø 7 (REC North ref. 2014/940), and The Norwegian Data Inspectorate licensed the data. Study has conforms to the principles embodied in the Declaration of Helsinki.

Data sharing statement Data are available upon reasonable request.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Olena lakunchykova http://orcid.org/0000-0002-8972-3621
Tom Wilsgaard http://orcid.org/0000-0002-2709-9472

REFERENCES
1 Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37:3232–45.
2 Grigoriev P, Mesei F, Shkolnikov VM, et al. The recent mortality decline in Russia: beginning of the cardiovascular revolution? Popul Dev Rev 2014;40:107–29.
3 Nikitin VP, Makarenkova KV, Malutina SK, et al. [Blood lipid parameters in populations of Russia, Poland and Czech Republic: the Hapiee Study]. Kardiologia 2015;55:34–9.
4 Shestov DB, Deen AD, Klimov AI, et al. Increased risk of coronary heart disease death in men with low total and low-density lipoprotein cholesterol in the Russian Lipid Research Clinics Prevalence Follow-up Study. Circulation 1993;88:846–53.
5 Averina M, Nilsson Q, Breen T, et al. High cardiovascular mortality in Russia cannot be explained by the classical risk factors. The Arkhangelsk Study 2000. Eur J Epidemiol 2003;18:871–8.
6 Glei DA, Goldman N, Shkolnikov VM, et al. Perceived stress and biological risk: is the link stronger in Russians than in Taiwanese and Americans? Stress (Amsterdam, Netherlands) 2013;16:411–20.
7 Folsom AR, Namini V, Bell EI, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke 2013.
8 Namibi V, Li x, Chambless LE, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. Clin Chem 2013;59:1802–10.
9 Seliger SL, Hong SN, Christensen RH, et al. High-sensitivity cardiac Troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). Circulation 2017;135:1494–505.
10 De Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503–12.
11 Magnusson C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med 2016;283:330–43.
12 Di Castelnuovo A, Veronesi G, Costanzo S, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke. Stroke 2019;50:610–17.
13 Reactive Protein C. Coronary heart disease genetics collaboration. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.
14 Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132–40.
15 Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388–97.
16 Koivistoinen S, Malutina S, Kudryavtsev A, et al. Know your heart: rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35–69 years from two Russian cities, 2015–18 [version 2; referees: 3 approved]. Wellcome Open Res 2018;3.
17 Mason C, Katzarovsk YP. Variability in waist circumference measurements according to anatomic measurement site. Obesity (Silver Spring) 2009;17:1789–95.
18 World Health Organization Collaborating centre for drug statistics methodology.
19 World Health Organization Monica project. MONICA manual, part Ic: event registration.
20 Lawlor D, Adamson J, Ebrahim S. Performance of the WHO Rose angina questionnaire in post-menopausal women: are all of the questions necessary? *J Epidemiol Community Health* 2003;57:538–41.
21 Egger M, Dieplinger B, Mueller T. One-year in vitro stability of cardiac troponins and galectin-3 in different sample types. *Clin Chim Acta* 2018;476:117–22.
22 Shalnova SAVVG, Metelskaya VA, Balanova JA, et al. Thirty-year changes in average blood lipids levels in populations of the Russian federation and the USA. *Ration Pharmacother Cardiol* 2018;14:2018.4–11.
23 Leon DA, Skolnikov VM, Borinskaya S, et al. Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies. *Eur J Epidemiol* 2013;28:393–404.
24 Tolonen H, Keil U, Ferrario M, et al. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. *Int J Epidemiol* 2004;34:181–92.
25 Driscoll A, Barnes EH, Blankenberg S, et al. Predictors of incident heart failure in patients after a acute coronary syndrome: the LIPID heart failure risk-prediction model. *Int J Cardiol* 2017;248:361–8.
26 Chua W, Purmah Y, Cardoso VR, et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. *Eur Heart J* 2019;40:1268–76.
27 Willett P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. *J Am Coll Cardiol* 2017;70:558–68.
28 Takashio S, Yamamuro M, Uemura T, et al. Correlation between extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure. *Am J Cardiol* 2014;113:1697–704.
29 Kawasaki T, Sakai C, Harimoto K, et al. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2013;112:867–72.
30 Chin CW, Messika-Zeitoun D, Shah AS, et al. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. *Eur Heart J* 2015;37:713–23.
31 Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *New Eng J Med* 2009;361:2538–47.
32 Averina M, Nilssen O, Arkhipovsky VL, et al. C-reactive protein and alcohol consumption: is there a U-shaped association? Results from a population-based study in Russia. *The Arkhangel'sk study. Atherosclerosis* 2006;188:309–15.
33 Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *New Eng J Med* 2002;347:1557–65.
34 Geluk CA, Post WI, Hilleges HL, et al. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. *Atherosclerosis* 2008;196:372–82.
35 Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease: a perspective. *Drug Des Devel Ther* 2010;4:383–413.
36 Eggen AE, Mathiesen EB, Wilsgaard T, et al. The sixth survey of the Tromsø Study (Tromsø 6) in 2007–08: collaborative research in the interface between clinical medicine and epidemiology: study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey. *Scand J Public Health* 2013;41:65–80.
37 lakunchykova O, Averina M, Kudryavtsev AV, et al. Evidence for a direct harmful effect of alcohol on myocardial health: a large cross-sectional study of consumption patterns and cardiovascular disease risk biomarkers from Northwest Russia, 2015 to 2017. *J Am Heart Assoc* 2020;9:e014491.